HeartBeam (NASDAQ: BEAT) announced the launch of a pilot study to evaluate its proprietary on-demand 12-lead ECG patch for detecting coronary artery disease and ischemia, a condition marked by inadequate blood flow and oxygen supply to tissue. The study marks a significant milestone in developing a patch-based device that could transform the $2 billion long-term continuous monitor and mobile cardiac telemetry (MCT) markets.
Coronary artery disease remains a leading cause of death globally, often progressing silently until a major cardiac event occurs. The ability to detect ischemia earlier and more conveniently could improve patient outcomes and reduce healthcare costs. According to HeartBeam CEO Robert Eno, "Ischemia detection has not been possible on patch-based ambulatory monitors, and they do not provide clinical-grade insights over an extended period of time. The HeartBeam patch is designed to change that."
The HeartBeam patch is intended to provide on-demand 12-lead ECG recordings, offering clinical-grade data that current patch monitors cannot deliver. If successful, the device could enable earlier identification of high-risk patients, potentially preventing heart attacks and other cardiac events. The pilot study will assess the patch's ability to detect ischemia in patients with known or suspected coronary artery disease.
This development comes as cardiovascular risk factors become more prevalent with an aging population. The global burden of coronary artery disease continues to intensify, driving demand for innovative diagnostic tools. HeartBeam's technology aims to bridge the gap between traditional in-hospital ECG monitoring and ambulatory patch systems, which have historically lacked ischemia detection capabilities.
The company plans to use findings from the pilot study to refine the device and support further clinical validation. A successful outcome could position HeartBeam to capture a significant share of the ambulatory monitoring market, which is currently dominated by devices that offer limited diagnostic information. The study's results are expected to be announced in the coming months.
For more information about HeartBeam and its technology, visit the company's newsroom at https://ibn.fm/BEAT. Forward-looking statements in this article are subject to risks and uncertainties, as detailed in HeartBeam's filings with the SEC.
